



truscreen
a world without
cervical cancer

NZX Announcement

9 December 2020

PUBLIC OFFER ACCEPTANCE REACHES TARGET NZ\$1.5 MILLION

As announced to the market on 9 and 26 November 2020, cervical cancer screening technology company, TruScreen Group Limited (NZX: TRU)(TruScreen or the Company) capital raising initiative, by way of a public offer, to raise up to NZD\$2 million (“Offer”) in conjunction with TruScreen’s application for the dual listing of its shares on the Australian Securities Exchange (ASX), closes on 18 December 2020.

TruScreen is pleased to advise that acceptances have already achieved the planned raise of NZ\$1.5m and the Board has resolved to accept further applications of up to NZ\$500,000 as oversubscriptions, per the maximum raise of NZ\$2 million as stated in the Product Disclosure Statement (PDS).

Applications can be made through the online application portal at <https://www.truscreenshareoffer.co.nz/>. A copy of the registered PDS in support of the Offer is available on the online application portal. Australian applications can be made at www.onmarket.com.au

An application has been made to the ASX for TruScreen to be admitted to the Official List of ASX as an ASX Foreign Exempt Listing and for quotation of the new shares to be offered in Australia on the ASX.

If TruScreen is admitted to the official list of ASX, then those Australian based investors in the Offer will initially have their Shares quoted on the ASX. Once dual listed, shareholders can select either the Australian or New Zealand sub-register to hold their shares to suit their investment needs.

The Offer is conditional upon the ASX approving the admission of TruScreen to the Official List of the ASX as an ASX Foreign Exempt Listing and for the quotation of the new shares issued to Australian investors on the ASX on or before that Closing Date (as that date may be varied from time to time). In the event that this condition is not satisfied, then the Offer will not proceed, and all application moneys received by the Company will be refunded to investors in full and without deduction within 5 business days.

-ENDS-

For more information, visit www.truscreen.com or contact:

Victoria Potarina
Chief Executive Officer
victoriapotarina@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com



About TruScreen:

TruScreen cervical cancer screening device offers the latest technology in cervical screening, providing real-time, accurate detection of precancerous and cancerous cervical cells to help improve the health and well-being of women around the world.

TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with conventional Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructure. As such, TruScreen's target market is low and middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is CE-marked and certified for use throughout Europe and NMPA (formerly CFDA) approved for sale in China. The global market potential for TruScreen is significant.